Skip to main content
UniHealth

Doctor search

Amina Chaudhry, MD

Medical Oncology · Stanford

NPI 1336679166

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
1
1 carrier
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

1 plan · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chaudhry’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A191287 · Current

Licensed to practise in California · since 2023 · expires 2027-09-30 · Ross University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

State licence records

1 licence

  • Illinois 036153343Licensed Physician And Surgeon · since 2020 · expires 2023-07-31
    Not RenewedNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$34,512

Medicare paid this office $34,512 for 92 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)33$9,756$130
Initial hospital care with moderate level of medical decision making at least 75 minutes32$7,440$155
Long return visit (40+ min)22$6,556$173
New patient visit (60+ min)26$4,222$162

Who their Medicare patients are

92 Original Medicare patients in 2024. Average age 72 · Women 66% · Also on Medicaid 29% · Health risk score 1.88. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: Cancer 75% · High blood pressure 67% · Chronic kidney disease 34% · Diabetes 30% · Coronary heart disease 30% · Heart failure 29% · Atrial fibrillation 24% · COPD 20% · Depression 20% · Dementia 16% · Stroke 13%.

The office billed $125,218, Medicare allowed $43,315 and paid $34,512; for 254 services of 13 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Medicaid work

$6,864 in 2024

Medicaid paid $6,864 for 60 billed services this clinician did in 2024, up to 20 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)60$6,864
Medicaid work by year
202460120$6,864

Drugs they prescribed that Part D paid

$593,698

Pharmacies billed $593,698 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

182 generic and 45 brand-name prescriptions · $593,698 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Ibrance27$408,973$15,147
Ondansetron30$588$20
Anastrozole34$519$15
Dexamethasone13$318$24
Prochlorperazine Maleate22$225$10
See all 7 drugs
Every Part D drug this clinician prescribed
Ibrance27$408,973$15,147
Ondansetron30$588$20
Anastrozole34$519$15
Dexamethasone13$318$24
Prochlorperazine Maleate22$225$10
Lidocaine-Prilocaine11$127$12
Lorazepam22$52$2

Year by year

Part D prescribing by year
202422742None20%$593,698
202313None0% (0)None$590
202243200% (0)None$13,351
202144230% (0)32%$89,244
202021None0% (0)None$1,619
20195622NoneNone$3,407
201815NoneNoneNone$2,076
201715None0% (0)None$4,537

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2022: 1 drug

Part D drugs prescribed in 2022
Tamoxifen Citrate11$230$21

Money from drug and device companies

$253 in 2025

Industry payments by year
202534None$253
202434None$206
202322None$313
202214None$143
202145None$386

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AstraZeneca Pharmaceuticals LPEnhertu$159
2 payments
  • Meals · 2025-12-10 · $43
  • Meals for Enhertu · 2025-11-11 · $115
Genentech USANone$68
1 payment
  • Meals · 2025-06-01 · $68
Daiichi SankyoEnhertu$26
1 payment
  • Meals for Enhertu · 2025-10-08 · $26
See all 4 published payments
Every published payment
AstraZeneca Pharmaceuticals LPMeals · 2025-12-10None$43
AstraZeneca Pharmaceuticals LPMeals · 2025-11-11Enhertu$115
Daiichi SankyoMeals · 2025-10-08Enhertu$26
Genentech USAMeals · 2025-06-01None$68
See earlier years (2024, 2023, 2022, 2021)

2024: $206

Payments by company in 2024
Tempus AIXt Cdx$125
2 payments
  • Meals for Xt Cdx · 2024-12-12 · $87
  • Meals · 2024-08-15 · $38
Merck Sharp & DohmeNone$48
1 payment
  • Travel · 2024-04-11 · $48
GenentechKadcyla$34
1 payment
  • Meals for Kadcyla · 2024-01-18 · $34

2023: $313

Payments by company in 2023
E.R. Squibb & Sons L.L.C.None$189
1 payment
  • Meals · 2023-06-04 · $189
AstraZeneca Pharmaceuticals LPLynparza$125
1 payment
  • Meals for Lynparza · 2023-05-23 · $125

2022: $143

Payments by company in 2022
SeagenTukysa$143
4 payments
  • Meals for Adcetris · 2022-08-30 · $20
  • Education · 2022-07-07 · $100
  • Meals for Tukysa · 2022-05-09 · $18
  • Meals for Tukysa · 2022-05-09 · $4

2021: $386

Payments by company in 2021
Pharmacosmos TherapeuticsMonoferric$139
2 payments
  • Education for Monoferric · 2021-04-19 · $49
  • Education for Monoferric · 2021-04-19 · $90
GenzymeCablivi$125
1 payment
  • Meals for Cablivi · 2021-10-07 · $125
Lilly USANone$103
1 payment
  • Education · 2021-11-02 · $103
Merck Sharp & DohmeKeytruda$19
1 payment
  • Meals for Keytruda · 2021-09-23 · $19

Professional record

NPI
1336679166
Licence
CA A191287, IL 036.153343California A191287: Current · expires 2027-09-30Illinois 036153343: Not Renewed
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2017-06-14
NPI last updated
2024-04-17
NPI record certified
2024-04-17

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 840 S Wood St Ste 820-E, Chicago, IL, 60612 · 920 Madison Ave Ste 447, Memphis, TN, 38103